Results 11 to 20 of about 121,674 (149)

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease [PDF]

open access: yesResearch
Chimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking technology in tumor immunotherapy, has demonstrated unprecedented potential in the field of autoimmune diseases in recent years.
Wenxia Shao   +3 more
doaj   +2 more sources

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation

open access: yesFrontiers in Immunology, 2022
Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a CD28-containing second generation CAR is
Leena Halim   +13 more
doaj   +1 more source

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

open access: yesNature Communications, 2021
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented ...
Michael S. Hwang   +21 more
doaj   +1 more source

Next-Generation Chimeric Antigen Receptor T-cells

open access: yesHematology/Oncology and Stem Cell Therapy, 2022
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene ...
Dongni Yi   +6 more
doaj   +1 more source

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

open access: yesImmunoMedicine, 2022
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies ...
Yue Huang, Mi Shao, Yiyun Wang, He Huang
doaj   +1 more source

An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells

open access: yesTranslational Research in Urology, 2020
Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh   +1 more
doaj   +1 more source

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report

open access: yesCritical Care Explorations, 2021
BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH   +4 more
doaj   +1 more source

CAR-T cell therapy for hematological malignancies: History, status and promise

open access: yesHeliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang   +3 more
doaj   +1 more source

Engineering Chimeric Antigen Receptors [PDF]

open access: yesActa Naturae, 2017
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens.
S V, Kulemzin   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy